Concepedia

Tjerk Bueters

TB

26

Publications

1.3K

Citations

18

H-Index

1997

Active since

Affiliations

AstraZeneca (Sweden)(Current)

Karolinska Institutet

Merck & Co., Inc., Rahway, NJ, USA (United States)

Uppsala University

AstraZeneca (United Kingdom)

Tjerk Bueters is an author at AstraZeneca (Sweden) specializing in medicine, pharmacology, and neuroscience.

ORCID

Top concepts

Publications per year

1997–2023

26

Publications

26

Reappearance of Hippocampal CA1 Neurons after Ischemia is Associated with Recovery of Learning and Memory

Olof Bendel, Tjerk Bueters, Mia von Euler et al. · Journal of Cerebral Blood Flow & Metabolism · 2005 · 169 citations · Full text

, , +23

A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors

Thomas J. Tucker, Mark W. Embrey, Candice Alleyne et al. · Journal of Medicinal Chemistry · 2021 · 140 citations · Full text

Discovery of AZD3839, a Potent and Selective BACE1 Inhibitor Clinical Candidate for the Treatment of Alzheimer Disease

Fredrik Jeppsson, Susanna Eketjäll, Juliette Janson et al. · Journal of Biological Chemistry · 2012 · 134 citations · Full text

Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor

Douglas G. Johns, Louis‐Charles Campeau, Puja Banka et al. · Circulation · 2023 · 118 citations · Full text

Selective effects of carbamate pesticides on rat neuronal nicotinic acetylcholine receptors and rat brain acetylcholinesterase

Chantal Smulders, Tjerk Bueters, Regina G.D.M. van Kleef et al. · Toxicology and Applied Pharmacology · 2003 · 101 citations

, , +11

Rows per page

1–5 of 26